Erratum: M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, L.A. Teoh, S.A. Fischkoff, and E.K. Chartash. Adalimumab, a Fully Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, for the Treatment of Rheumatoid Arthritis in Patients Taking Concomitant Methotrexate: The ARMADA Trial, Arthritis & Rheumatism (2003) 48(1) 35-45.

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 39 KB
• Volume: 48
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.546

✦ Synopsis

Abstract

The original article to which this Erratum refers was published in Arthritis & Rheumatism(2003) 48(1) 35–45

In the article by Weinblatt et al published in the January 2003 issue of Arthritis & Rheumatism (pp 35–45), there was an error in data reported in the first paragraph of the Results section (page 37). The fourth sentence of that paragraph should have read, “Of these 92 rollover patients, 23, 17, and 17 were in the adalimumab 20 mg, 40 mg, and 80 mg groups, respectively, and 35 were in the placebo group.”

We regret the error.